AdOTAC is a pilot study, open, prospective, single-center, one-arm. The 200 patients will be included. Patient is included at Day 0. The included patient will have the opportunity to complete the self-questionnaires either at the ICL on Day 0, or at home up to 10 days after the date of inclusion in the study. Blood samples are collected the day of enrolment (Day 0) in order to measure the following biological markers: ferritin, serum iron, TSAT, albumin, and haemoglobin, except if performed as part of routine care in the previous 6 weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
200
Ferritin, Transferrin Saturation (TSAT), Serum iron, Haemoglobin, Albumin
GIRERD questionnaire, AdOT questionnaire, Use of social networks and alternatives and complementary medicines using patient questionnaire, EORTC QLQC30, HADS, MNA, MSPSS
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, France
Assess medication adherence to oral treatments in patients with advanced breast or prostate cancer.
Medication adherence to oral anticancer treatments will be assessed using a score based on the GIRERD adherence assessment (targeting oral anticancer treatments). The score is a scale ranging from 0 to 6 (good compliance = 6; poor compliance = 4 to 5; non-adherence ≤ 3).
Time frame: one day
Identify if the performance status by the ECOG-PS score is associated with reduced adherence to oral anticancer treatments
The performance status by the ECOG-PS score (0 to 4).
Time frame: one day
Identify if comorbitities is associated with reduced adherence to oral anticancer treatments
Comorbidities using the Charlson score (0 to 37).
Time frame: one day
Identify if polypharmacy by the use of five or more medications apart from the current oral anti-cancer medications is associated with reduced adherence to oral anticancer treatments
Polypharmacy by the use of five or more medications apart from the current oral anti-cancer medications (0 to \>5).
Time frame: one day
Identify if treatment regimen by a level of complexity is associated with reduced adherence to oral anticancer treatments
The treatment regimen by a level of complexity (4 levels) given by an oncologist.
Time frame: one day
Identify if biological markers are associated with reduced adherence to oral anticancer treatments
Biological markers (ferritin, TSAT, serum iron, haemoglobin, albumin) by a blood test.
Time frame: one day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Identify if sarcopenia is associated with reduced adherence to oral anticancer treatments
Sarcopenia by the body mass/fat mass ratio using imaging (SMI: skeletal muscle mass index).
Time frame: one day
Identify if quality of life using the EORTC-QLQ-C30 questionnaire score is associated with reduced adherence to oral anticancer treatments
Quality of life using the EORTC-QLQ-C30 questionnaire score.
Time frame: one day
Identify if Social and emotional support by the MSPSS questionnaire is associated with reduced adherence to oral anticancer treatments
Social and emotional support by the MSPSS questionnaire (Multidimensional Scale of Perceived Social Support) (12-35: low perceived support; 36-60: medium perceived support; 61-84: hugh perceived support)
Time frame: one day
Identify if HADS scale is associated with reduced adherence to oral anticancer treatments
Anxiety and/or depression using the Hospital Anxiety and Depression Scale (HADS). (If the score in a column is greater than or equal to 11, it means person suffer from anxiety or depression)
Time frame: one day
Identify if MNA is associated with reduced adherence to oral anticancer treatments
Malnutrition using the MNA (Mini-Nutritional Assessment) questionnaire (24-30 points: normal nutritional status; 17-23.5 points: at risk of malnutrition; less than 17 points: malnourished)
Time frame: one day
Identify if Use of social networks and alternatives and complementary medicines using patient questionnaire is associated with reduced adherence to oral anticancer treatments
Use of social networks and alternatives and complementary medicines using patient questionnaire developed specifically for the study population.
Time frame: one day
Assess medication adherence to oral treatments in patients with advanced breast or prostate cancer.
Medication adherence to oral anticancer treatments will also be assessed using the score from the new AdOT questionnaire. The score is a scale ranging from 0 (no adherence) to 100 (perfect adherence).
Time frame: one day
Study the relationship between the two adherence questionnaires.
Subgroup analysis by cancer type (breast; prostate), use of alternatives and complementary medicines (yes; no) and use of social media and networks (yes; no).
Time frame: one day
Describe and compare medication adherence to oral treatments
The correlation between the scores on the GIRERD and AdOT will be analysed.
Time frame: one day
Describe and compare patient characteristics (socio-demographic, clinical and contextual), medication adherence to oral anticancer treatments according to cancer type, use of alternative and complementary medicines and use of social media and networks.
Subgroup analysis by cancer type (breast; prostate), use of alternative and complementary medicines (yes; no) and use of social media and networks (yes; no).
Time frame: one day